MCO formulary managers for a migraine treatment that has a good chance of relieving pain within 15 minutes, allowing quick return to normal activities. We also found that patients and physicians are willing to pay much more than MCO formulary managers for other quality-of-life benefits, including preferred dosage form, nausea relief and avoiding drowsiness.
Despite insomnia induces a great number of medical and psychiatric visits, the role of co-morbidity in the medical and professional consequences of this sleep disorder is poorly documented. OBJECTIVES: Our study seeks to evaluate the impact of insomnia on the health status and absenteeism; and to identify the part of co-morbidity in the severity of insomnia. METHODS: We used data from the Gazel cohort (a cohort of employees of the French electrical and gas company) providing medical, professional and demographic information; the Epworth sleepiness scale; the Nottingham Health Profile; the Basic Nordic Sleep Questionnaire and a 3-week sleep log. Firstly, we compared a group of insomniacs (n = 986) with another one free of sleep complaints (n = 584). Secondly, all subjects suffering from mood and organic sleep complaints (snoring and nocturnal periodic leg movements) were excluded. RESULTS: In the non-adjusted by mood and organic sleep complaints comparison (n = 986) we found a higher absenteeism than in insomniac group than in control (9.6 +/-31 days versus 5.8 +/-19 days, U Mann-Withney, p < 0.01). However, no differences (6.39 vs. 6.02 days, U Mann-Withney, p = NS) in absenteeism between the control group and insomniacs free of depression or organic sleep complaints were observed. Nevertheless, insomniacs (complaining or not of mood or organic sleep complaints) showed a poorer health status defined by the Nottingham Health Profile than control subjects. CONCLUSIONS: Insomniac complaints are strongly associated with an alteration of quality of life. Absenteeism in insomniacs is related to associated mood disorders or organic sleep complaints. . This study has provided also data on the burden of migraine in terms of its economic and social impact. We would like today to update the data. METHODS: 1486 persons, aged over 15 and suffering from headaches were randomly selected from a large representative sample of the French population. They were asked to complete a questionnaire, which allowed discriminating sufferers of migraine according to IHS criteria. RESULTS: Among the 1486 headache sufferers, we find 880 migrainous people (1-1, 1-2 and 1-7 IHS criteria), 454 without migrainous headache and 152 with chronic daily headache. If we compare the results of the certain migraine group (1-1 and 1-2 IHS) we find that they are identical (8.1% (1989) versus 8.2% (1999) ). However, if we include the migrainous disorder group fulfilling all criteria but one (1-7 IHS), the prevalence rate for migraine headache in France between 1989 and 1999 seems to show a clear increase, rising from 12.1% to 17.3% because of less restrictive criteria than those applied ten years ago. Regarding the prevalence in general population for chronic daily headache the rate is around 3% with 1.8% for men and 3.9% for women in 1999.
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